GVAX cancer vaccine consisting of a patient's cancer cells modified ex vivo with the gene to produce GM-CSF: Began Phase I dose-scheduling trial of three to fiv

Somatix Therapy Corp. ( SOMA), Alameda, Calif. Product: GVAX cancer vaccine consisting of a patient's cancer cells modified ex vivo with the gene to produce GM-CSF, and reinjected Indication: Melanoma...